Decoy Therapeutics Highlights Global Access Commitment Agreement in Virtual Investor Segment

Company discusses plans to develop scalable manufacturing platform for peptide-conjugate antivirals with focus on expanding access in low- and middle-income countries.

Feb. 4, 2026 at 8:31am

Got story updates? Submit your updates here. ›

Decoy Therapeutics, a preclinical biopharmaceutical company, announced that it participated in a Virtual Investor "What This Means" segment highlighting the company's recently announced Global Access Commitment Agreement (GACA) with the Gates Foundation. The segment provided additional context on Decoy's plans to develop a flexible, globally accessible, and scalable manufacturing platform for peptide-conjugate antivirals, which is a key funded development under the GACA.

Why it matters

Decoy's "design-for-manufacturing" approach aims to enable rapid transition of peptide-conjugate therapeutics from lab to commercial-scale production, and to establish a distributed global manufacturing network capable of responding to emerging viral threats. This aligns with the company's goal of expanding access to its therapies, particularly in low- and middle-income countries.

The details

As part of the segment, Decoy's Chief Business Officer Peter Marschel discussed how the company's platform is designed to enable rapid, cost-efficient manufacturing and scale-up of therapeutics developed through Decoy's proprietary IMP3ACT™ platform. The platform will be validated using Decoy's intranasal pan-coronavirus fusion inhibitor, which is also funded under the Gates Foundation grant.

  • The "What This Means" segment was aired on February 4, 2026.

The players

Decoy Therapeutics, Inc.

A preclinical biopharmaceutical company that is engineering the next generation of peptide conjugate therapeutics.

Peter Marschel

Chief Business Officer of Decoy Therapeutics.

Gates Foundation

A global health and development organization that has provided funding to Decoy Therapeutics through a Global Access Commitment Agreement.

Got photos? Submit your photos here. ›

What they’re saying

“The platform is designed to enable rapid, cost-efficient manufacturing and scale-up of therapeutics developed through Decoy's proprietary IMP3ACT™ platform, with a focus on expanding access in low- and middle-income countries.”

— Peter Marschel, Chief Business Officer

What’s next

Decoy plans to validate its globally accessible and scalable manufacturing platform using its intranasal pan-coronavirus fusion inhibitor, which is funded under the same Gates Foundation grant.

The takeaway

Decoy Therapeutics' efforts to develop a flexible and scalable manufacturing platform for peptide-conjugate antivirals, with a focus on expanding access in low- and middle-income countries, demonstrate the company's commitment to making its therapies widely available and responsive to emerging global health threats.